²é¿´: 1358  |  »Ø¸´: 4
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

laberlee

ľ³æ (СÓÐÃûÆø)

[½»Á÷] ¡¾ÇóÖú¡¿ÇóÓйذ¢´ïľµ¥¿¹µÄ·¢ÏÖ¡¢ÁÙ´²Ç°Ñо¿¡¢ÁÙ´²Ñо¿£¬FDAÉêÇ룬¼¼Êõ×ªÒÆµÄÓйØÎÄÏ ÒÑÓÐ3È˲ÎÓë

ÏÈллÁË¡£¡£ÎÒʵÔÚËѲ»µ½
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

hardee

Ìú¸Ëľ³æ (ÖªÃû×÷¼Ò)

´Ë²ÝÓÐÖ÷~

¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
chinarencxp(½ð±Ò+1): ¹ÄÀø»ý¼«½»Á÷ 2011-04-16 22:20:18
Ëæ±ã¿´¿´°É£º

Title: Adalimumab

CAS Registry Number: 331731-18-1

CAS Name: Anti-(human tumor necrosis factor) immunoglobulin G1 (human monoclonal D2E7 heavy chain) disulfide with human monoclonal D2E7 light chain, dimer

Manufacturers' Codes: D2E7

Trademarks: Humira (Abbott)

Literature References: Fully human monoclonal antibody against tumor necrosis factor a (TNFa). Prepn: J. G. Salfeld et al., WO 9729131; eidem, US 6090382 (1997, 2000 both to BASF). Characterization: L. C. Santora et al., Anal. Biochem. 275, 98 (1999). Characterization of antigen binding: idem et al., ibid. 299, 119 (2001). Clinical trial in rheumatoid arthritis: A. A. den Broeder et al., Ann. Rheum. Dis. 61, 311 (2002); in combination with methotrexate: F. C. Breedveld et al., Arthritis Rheum. 54, 26 (2006); in psoriatic arthritis: P. J. Mease et al., ibid. 52, 3279 (2005). Review of pharmacology and clinical experience: K. P. Machold, J. S. Smolen, Expert Opin. Biol. Ther. 3, 351-360 (2003). Review of safety and efficacy in psoriasis and rheumatoid arthritis: T. Patel, K. B. Gordon, Dermatol. Ther. 17, 427-431 (2004); in psoriatic arthritis: P. J. Mease, Expert Opin. Biol. Ther. 5, 1491-1504 (2005).

Therap-Cat: Anti-inflammatory.

Keywords: Anti-inflammatory (Biological Response Modifier).
°²µÃ´ÙÏ¥£¬¿É¹²Æ½Éú¡£
3Â¥2011-04-16 08:36:54
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ laberlee µÄÖ÷Ìâ¸üÐÂ
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û